ISTURISA (osilodrostat) by Recordati is inhibitor. Approved for cushing's syndrome, cushing's disease. First approved in 2020.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
ISTURISA (osilodrostat) is an oral 11beta-hydroxylase inhibitor approved by the FDA in March 2020 for treating endogenous hypercortisolemia in adults with Cushing's syndrome who are not candidates for surgery. The drug works by inhibiting CYP11B1, the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland, with demonstrated IC50 values of 2.5 nM in human cell lines. As the first oral 11beta-hydroxylase inhibitor on the market, it represents a significant advancement for a rare endocrine disorder with limited treatment options.
inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In a Chinese hamster lung cell line V79-4 that overexpresses human CYP11B1, adrenodoxin and adrenodoxin reductase, osilodrostat inhibited the activity of…
Worked on ISTURISA at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moISTURISA creates career opportunities for specialty pharmaceutical professionals including brand managers, medical science liaisons targeting endocrinologists and rare disease specialists, and field sales representatives focused on hospital and specialty pharmacy channels. Success requires deep knowledge of Cushing's syndrome pathophysiology, rare disease marketing, and ability to work with small, specialized physician networks. Currently, zero linked job openings are identified for ISTURISA-specific roles, though the product's market maturity and established formulary position suggest stable team-based support.